Navigation Links
UC San Diego among first in nation to treat brain cancer with novel viral vector
Date:3/1/2012

UC San Diego Moores Cancer Center researchers and surgeons are among the first in the nation to treat patients with recurrent brain cancer by directly injecting an investigational viral vector into their tumor. The treatment is being developed by a local San Diego Company, Tocagen Inc.

"This clinical trial targets glioblastoma one of the deadliest forms of brain tumor," said principal investigator Santosh Kesari, MD, PhD, director of neuro-oncology in the Moores Cancer Center and in the Department of Neurosciences at the University of California, San Diego. "Clinical trials of investigational therapies such as this may lead to new treatment options for patients battling this deadly disease."

The current standard of care for a newly diagnosed, high-grade glioma includes surgically removing as much of the tumor as possible, followed by radiation therapy and chemotherapy. Despite these measures, the tumor usually recurs making this trial a high priority.

The trial is investigating the use of Toca 511 (vocimagene amiretrorepvec), for injection in combination with Toca FC (flucytosine), extended-release tablets. Toca 511 is a retroviral replicating vector (RRV) that is designed to deliver a cytosine deaminase (CD) gene selectively to cancer cells. After allowing time for the administered Toca 511 to spread through the cancerous tumor those cancer cells expressing the CD gene can convert flucytosine into the anti-cancer drug 5-fluorouracil (5-FU). In this study, patients receive cycles of oral Toca FC monthly for up to six months.

"This may provide a way to destroy the cancer cells without disrupting delicate neurocircuitry," explained surgeon scientist Clark Chen, MD, PhD, director of stereotactic and radiosurgery, UC San Diego Moores Cancer Center and an investigator on the study. Chen administered Toca 511 into the first patients who have participated in this clinical trial at UC San Diego. "We fused the patient's CT scan to their MRI and used neuro-navigation software to calculate exactly where in the tumor we needed to place the injection of Toca 511. The patients were given the injection and discharged from the hospital the day after the procedure."

Co-investigator Bob Carter, MD, PhD, chief of the Division of Neurosurgery at UC San Diego Medical Center and Moores Cancer Center, noted that this novel agent is the culmination of years of multi-disciplinary efforts. "Tocagen's investigational therapy, Toca 511 & Toca FC, is a representative example of the culmination of many technological advances that have come to pass during the last three decades," said Carter. "It is a convergence of years of hard work by dedicated public and private practitioners in many different fields including molecular biologists, basic scientists, virologists, physicists, mathematicians, surgeons, computer scientists, manufacturing experts, regulatory experts, and oncologists."

For Kesari, whose doctoral thesis focused on viral therapy for brain tumors, this has been a passion for 20 years. "I started this kind of research two decades ago, and to see a new technology like Toca 511 advance from bench to bedside completes the circle. This is the moment physician-researchers live for."

"This trial is an exciting realization of the ability to help our patients that comes from outstanding science combined with innovative thinking and the desire to deliver compassionate care," said William C. Mobley, MD, PhD, chair of the Department of Neurosciences at the UC San Diego School of Medicine. "At UC San Diego, we are intent upon transforming the care of patients with disorders of the brain."


'/>"/>

Contact: Kim Edwards
kecwards@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. UC San Diegos William C. Mobley recognized for contributions to Down syndrome
2. AAAS Pacific Division to convene joint session with world mummy scholars in San Diego
3. Study finds Filipino children in San Diego County at higher risk for Kawasaki disease
4. UC San Diego receives 2 major biomedical informatics grants
5. UC San Diego researchers identify factor boosting leukemias aggressiveness
6. La Jolla Institute to develop San Diegos first center for RNAi genomics research
7. UC San Diego partners with Mozambique University to deliver quality health care
8. UC San Diego researcher awarded $3.8 million for new path to breast cancer therapy
9. Type 1 diabetes research at UC San Diego gets $5 million boost
10. UC San Diegos Karin receives prestigious Harvey Prize
11. APA presents latest research on same-sex marriage at annual convention in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC San Diego among first in nation to treat brain cancer with novel viral vector
(Date:5/4/2016)... Ventura, CA (PRWEB) , ... May 04, 2016 , ... ... cutting-edge technology to help restore its patients’ health, is hosting a free seminar on ... and will be held at Advanced Spine & Sport, 4601 Telephone Road, Suite 110, ...
(Date:5/4/2016)... ... 2016 , ... AudioEducator is the country's top training providers ... has lined up some informative training session for the medical coding and billing ... and practical, easy-to-apply advice. , On Thursday, May 19, AudioEducator will host a ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and elbows. Engineered with athletes in mind, OMNIFORCE offers high-performance, less bulk, ... circular knitting, common in the industry) produces premium flat-knit construction with “focused ...
(Date:5/4/2016)... City, Nevada (PRWEB) , ... May 04, 2016 , ... ... bladder infections. Bladder infections, also called UTIs, have plagued people since the beginning ... millions of women get bladder infections every year. It's not just a matter of ...
(Date:5/4/2016)... ... May 03, 2016 – (PRWEB) May ... and child products, today revealed the non-toxic benefits of its Tutti ... deal with teething pain is just part of the story. These ... are BPA-, PVC-, and phthalate-free. , “Many baby toys contain ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... India , May 4, 2016 ... spreads across 154 pages, profiling 09 key companies ... is a professional and in-depth study on the ... a basic overview of the industry including definitions, ... Needles market analysis is provided for the international ...
(Date:5/3/2016)... 3, 2016 BioNovus Innovations LLC and ... Advancing Medical Innovation (IAMI) today announced a new ... and medical devices. An agreement between ... to license, develop and commercialize medical innovations advanced ... "This partnership represents a significant advance in our ...
(Date:5/3/2016)... 4, 2016 Research and Markets ... Stem Cell Therapy Market Outlook 2020" report to ... ) , ,Recombinant technology has improved significantly in past ... be developed in coming years. Many cancer drugs have ... cell therapies are also expected to be developed with ...
Breaking Medicine Technology: